Wockhardt Limited announced its Un-audited Financial Results for the quarter and half-year ended September 30, 2026. The company reported a 24% year-on-year revenue growth for Q2 FY27, reaching INR 969 Cr. EBITDA also saw a substantial increase, reflecting positive momentum across its business segments. The press release highlights advancements in novel antibiotics and biosimilar segments, underscoring strategic growth initiatives.
Wockhardt Reports Strong Financial Performance for Q2 FY27
Wockhardt Limited, a major player in the pharmaceutical and biotechnology sector, has announced its financial results for the second quarter and first half of the Financial Year 2026-27, ending September 30, 2026. The company showcased robust growth, with revenue for Q2 FY27 reaching INR 969 Cr, a significant increase of 24% compared to the previous year. This performance indicates strong operational momentum and market traction.
Financial Highlights
Q2 FY27 Performance
The company’s revenue for the quarter stood at INR 969 Cr, up from INR 782 Cr in the corresponding period last year. EBITDA was reported at INR 165 Cr, a slight increase from INR 160 Cr in Q2 FY26. Excluding pre-ZAYNICH launch expenses, EBITDA was INR 201 Cr. Profit Before Tax (PBT) stood at INR 73 Cr, and Profit After Tax (PAT) was also INR 73 Cr.
H1 FY27 Performance
For the first half of FY27, Wockhardt’s revenue grew by 25% to INR 1,898 Cr, compared to INR 1,520 Cr in H1 FY26. EBITDA for H1 FY27 was INR 353 Cr, showing a substantial 35% growth from INR 261 Cr in the prior year. EBITDA, excluding pre-ZAYNICH launch expenses, was INR 398 Cr. PBT for the half-year was INR 189 Cr, and PAT stood at INR 180 Cr.
Biosimilar Business Growth
The Biotech operations demonstrated impressive growth, with Q2 FY27 revenue at INR 252 Cr, marking a 68% increase year-on-year. On a half-yearly basis, Biotech operations recorded INR 487 Cr with an 87% growth. This performance is attributed to the strong expansion of the Emerging Market biotech segment, which grew by approximately 110% in H1 FY27, driven by new market acquisitions and strategic partnerships in regions like Brazil, Thailand, Egypt, Algeria, and LATAM. India’s Biotech operations also continue to exhibit double-digit growth.
Regional Business Performance
India & Emerging Market
India Branded Business reported INR 146 Cr in Q2 FY27, an 8% growth year-on-year. H1 FY27 saw this segment reach INR 303 Cr, with a 14% growth. This expansion was fueled by performance in the Diabetic therapy, NCE (EMROK), and the introduction of the Regenerative Derma segment. The Emerging Markets region achieved INR 310 Cr in Q2 FY27, a notable 52% growth, with H1 FY27 revenue at INR 574 Cr (up 54%), largely driven by the Biotech Insulin segment and Latam operations.
EU & UK
The UK region reported GBP 28 Mn in Q2 FY27, a 4% growth, and GBP 55 Mn in H1 FY27 with a 2% growth. The Irish region recorded EUR 6 Mn in Q2 FY27 and EUR 11 Mn in H1 FY27, reflecting a 13% growth.
New Products and Key Updates
Wockhardt has made significant strides in new product launches and approvals. The company reported 24 filings, 18 approvals, and 11 launches in its international business, including 2 Biosimilars filings and 4 approvals. Notably, approval was received for EMROK O and EMROK injection in Uganda.
Novel Antibiotics
Five Novel Antibiotics from Wockhardt have successfully completed Phase 3 Clinical Trials: Emrok®, Emrok O®, Miqnaf®, Zaynich®, and Foviscu®. Zaynich® has received approval for manufacturing and marketing in India, and gained US FDA approval on May 29, 2026, for cUTI and Pyelonephritis. The EMA review process is progressing smoothly. EMROK® and EMROK-0 have shown a strong growth rate of 40% vs previous year Q2 FY26 and 37% vs previous year H1 FY26, treating approximately 150,000 patients and are on track to lead the anti-MRSA therapy segment. MIQNAF® NAFITHROMYCIN has been approved and launched in India, enhancing market access and clinical acceptance. FOVISCU® (WCK 4282) has successfully completed India Phase 2 & 3 Clinical Trials, with an NDA filing completed recently.
Intellectual Property Update
During Q2 FY27, Wockhardt filed 7 patents and was granted 6 patents. The cumulative filings to date stand at 3298, with the company holding 865 patents. Wockhardt’s research focus is on unmet needs in anti-bacterial drugs to combat untreatable superbugs, with 6 of its anti-bacterial discovery programs having received USFDA QIDP Status.
Source: BSE
